Anagenex

Check out how Kayla Pukys at Anagenex was able to automate 15 parallel organic chemistry reactions in only hours with Spaero instead of taking weeks to write, optimize, and troubleshoot dozens of lines of code.

Our biology team recently took a break from the laboratory to compete in a few rounds of mini golf at Puttshack. Team-building opportunities offer a chance to get curious about the people you collaborate with and exercise creativity, and we love to see everyone having fun together!

Our research partners at Anagenex published an article in Biopharma Dealmakers, a Springer Nature Group publication, highlighting how they're combining ultra-throughput biochemistry and #machinelearning to address some of the hardest targets in drug discovery. We are proud to collaborate with Anagenex to discover precision small molecule therapeutics for multiple indications. Read the full article here: https://lnkd.in/eCa8dsFZ

We are excited to announce the first programs in our synthetic lethal oncology franchise. Our platform has discovered and is enabling the rapid optimization of differentiated PRMT5 and MAT2A programs that will help many more patients, fulfilling our mission to find a molecule for every malady. Read the full press release here: https://lnkd.in/dQ5Thsn9 #AI #drugdiscovery #biotech

Laboratory and office space enables our team to work towards our mission of finding a molecule for every malady, and we appreciate The Steele Group’s support to make sure our company has space to grow.

G. Joseph Franklin from Anagenex is discussing: "Combining Machine Learning and Screening Results to Enable Drug Discovery Programs" at #DDSS Stay tuned for more! #DDSS2024! #15thddss2024 #PharmaInnovation #UnlockPotential #summit2024 #staytunedformore

LaShadric Grady spoke about how Anagenex uses Protein Metrics to reduce manual data analysis and increase throughput at the Protein Metrics, LLC by Dotmatics user group meeting this week. Our team was thrilled at the opportunity to share their knowledge and discuss the future of drug discovery with other experts!

AI-Driven Drug Discovery Straddles the Virtual and the Real The AI approach—iteratively churning through masses of experimental and synthetic data—blurs the distinction between computation and biology. In this April issue article GEN spoke with Nicolas Tilmans, PhD, founder and CEO of Anagenex, Jen Nwankwo, PhD, co-founder and CEO of 1910 Genetics, and Jason Park, PhD, co-founder and CEO, Empress Therapeutics and Operating Partner, Flagship Pioneering.

Scale and speed are key in #generativeAI. Our computational and structure-based #drugdiscovery work is backed by leading-edge technologies. Last year we announced a collaboration with Anagenex to complement our early discovery efforts for multiple challenging targets. Read more about our collaboration via Pharmaceutical-Technology: https://lnkd.in/d6n4vHHE 

Sometimes our team gets to put down the pipettes and pick up a paintbrush! We had a fun evening at Pinot’s Palette where everyone painted a beautiful landscape, and discovered each cloud is as unique as the person painting it. These events are wonderful opportunities to experiment with trying something new and learn about each other in the process. We can’t wait to see what our activity committee comes up with for our next onsite! Thank you to Leah Ward, LaShadric Grady, Kaileigh Cloutier-LeBlanc, Neil Johnson, Olga Yuzhakov, and Joey Desarden for the best team-building ideas!